 He returned to academia as the Director of the UPDDI.His current research interests include the development and application of human microphysiology systems as more advanced experimental models for drug discovery and development, the application of quantitative systems pharmacology (QSP) for a new paradigm in drug discovery and computational and systems pathology to predict therapeutic strategies for a variety of diseases.He is the co-founder and Chairman of SpIntellx, a computational and systems pathology company with focus on spatial analytics and explainable AI (xAI).